EGFR and non-small cell lung carcinoma: Furthermore, a phase I trial tested the combination of hydroxychloroquine and erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in EGFR-mutant non-small cell lung cancer; it demonstrated preliminary activity and acceptable tolerability [60].